Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesDrugs Administered Other than Oral MethodHCPCS hcpcs-j2781-pegcetacoplan-intravitreal-injection-1mg
    Ask Trek AI about this page

    HCPCS J2781: Injection, pegcetacoplan, intravitreal, 1 mg

    HCPCS Level II code J2781 describes the intravitreal injection formulation of pegcetacoplan, billed per 1 mg unit; this code represents administration of an ophthalmic complement inhibitor delivered via intravitreal injection as the service type, typically provided in an ophthalmology clinic, ambulatory surgery center, or hospital outpatient department for retinal disease management.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for hcpcs J2781 policy alerts

    Get alerted when payer policies referencing J2781 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) presenting for intravitreal therapy with pegcetacoplan. The patient has progressive central or paracentral vision loss documented on visual acuity testing and monitoring imaging (optical coherence tomography and fundus autofluorescence) showing enlarging areas of atrophy. Prior to injection there is a pre-procedure evaluation including informed consent, allergy review, medication reconciliation (antiplatelet/anticoagulant status), and measurement of visual acuity and intraocular pressure. The intravitreal injection of J2781 (pegcetacoplan, intravitreal, 1 mg) is performed in a procedure room or ambulatory surgery center under sterile technique: topical antisepsis with povidone-iodine, topical anesthesia, application of a lid speculum, and use of a calibrated needle to deliver the specified dose into the vitreous cavity. Post-injection care includes intraocular pressure check, topical antibiotic or anti-inflammatory drops per clinic protocol, documented post-procedure instructions, and scheduling of follow-up visits for monitoring efficacy and adverse effects (endophthalmitis, intraocular inflammation, elevated intraocular pressure). Documentation should include the drug name and dosage as J2781, lot number, expiration, injection site (right RT or left LT), procedure consent, and any applicable modifier(s) for billing and payer adjudication. Typical site of service is an ophthalmology clinic procedure room or ambulatory surgical center. Typical providers are retinal specialists (ophthalmology).

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    67028Intravitreal injection of a pharmacologic agent (separate procedure)Directly corresponds to the procedural service of administering J2781 intravitreally; often reported with the drug HCPCS when payer requires separate reporting of the administration procedure.
    92083Fundus photography with interpretation and report, extendedUsed for retinal imaging to document macular atrophy and monitor treatment response before or after injection.
    92134Scanning computerized ophthalmic diagnostic imaging, posterior segment, OCT, with interpretation and report; unilateral or bilateralCommonly performed pre- and post-injection for anatomic monitoring of geographic atrophy and to guide treatment decisions.
    99213Office visit for established patient, moderate complexityTypical evaluation and management visit for pre-procedure assessment or routine follow-up after intravitreal injection.
    67036Vitrectomy, pars plana; complex (includes removal of vitreous opacities)Related to the retina surgery spectrum; may be billed if a surgical complication of intravitreal injection requires pars plana vitrectomy.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    24Modifier 24 denotes an unrelated evaluation and management (E/M) service performed by the same physician or qualified healthcare professional during a postoperative global period. Per CPT guidance,…- Use modifier 24 when you report an evaluation and management (E/M) service performed by the same physician or same-specialty group during a procedure’s postoperative global period that is unrelated…
    99Modifier 99 is a placeholder modifier used when more modifiers apply to a single procedure than the claim form or electronic field allows. The AMA classifies it under Provider Services and Ambulatory…- Use CPT modifier -99 when more modifiers apply to a single procedure line than the claim form or payer field allows (CMS/Noridian: when more than four modifiers are needed); append modifier 99 on…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207W00000X
    207K00000X
    363LF0000X
    367500000X
    261QP1100X
    163WR1000X
    111NR0400X
    405300000X

    Related ICD-10-CM Codes

    8 rows

    ICD-10-CM CodeDescription
    E10.311Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
    E10.319Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
    E11.39Type 2 diabetes mellitus with other diabetic ophthalmic complication
    H26.9Unspecified cataract
    H35.30Unspecified macular degeneration
    H35.33Angioid streaks of macula
    H40.9Unspecified glaucoma
    H54.7Unspecified visual loss

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    VonvendiCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

    HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

    HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

    HCPCS Level II J0120: Injection, Tetracycline, up to 250 mg

    HCPCS-J0121-OMADACYCLINE-INJECTION-1MG

    HCPCS Level II J0121: Omadacycline Injection, 1 mg

    HCPCS-J0122-ERAVACYCLINE-INJECTION-1MG

    HCPCS Level II J0122: Injection, eravacycline, 1 mg

    HCPCS-J0129-ABATACEPT-INJECTION-10MG-PHYSICIAN-SUPERVISED

    HCPCS Level II J0129: Abatacept Injection, 10 mg

    HCPCS-J0130-INJECTION-ABCIXIMAB-10MG

    HCPCS Level II J0130: Injection abciximab, 10 mg

    HCPCS-J0131-INJECTION-ACETAMINOPHEN-10MG-PARENTERAL-ANALGESIC

    HCPCS Level II J0131: Injection, Acetaminophen 10 mg

    HCPCS-J0132-INJECTION-ACETYLCYSTEINE-100MG-INJECTABLE-MEDICATION

    HCPCS Level II J0132: Injection, Acetylcysteine 100 mg

    HCPCS-J0133-ACYCLOVIR-INJECTION-5MG

    HCPCS Level II J0133: Injection, Acyclovir 5 mg

    HCPCS-J0134-ACETAMINOPHEN-INJECTION-FRESENIUS-KABI-10MG

    HCPCS Level II J0134: Injection, Acetaminophen (10 mg)

    Showing 1–10 of 991

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.